Technology
Health
Biotechnology

Heat Biologics

$1.26
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.02 (-1.70%) Today
+$0.01 (0.93%) After Hours

Why Robinhood?

You can buy or sell Heat Biologics and other stocks, options, ETFs, and crypto commission-free!

About

Heat Biologics, Inc. Common Stock, also called Heat Biologics, is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. Read More The firm's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the firm's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Durham, NC.

Employees
19
Headquarters
Durham, North Carolina
Founded
2008
Market Cap
29.51M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
843.51K
High Today
$1.27
Low Today
$1.24
Open Price
$1.27
Volume
60.48K
52 Week High
$4.30
52 Week Low
$0.952

Collections

Technology
Health
Biotechnology
Medical
Cancer Prevention
2013 IPO
US
North America

News

MarketBeatMar 3

Stock Price, News, & Analysis for Heat Biologics

Heat Biologics, Inc., a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness. Its TCAP product candidates include ImPACT platform technology that develops product candidates...

179
Simply Wall StFeb 23

Is Heat Biologics, Inc. (NASDAQ:HTBX) Excessively Paying Its CEO?

Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! In 2008 Jeff Wolf was appointed CEO of Heat Biologics, Inc. (NASDAQ:HTBX). This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. Then we’ll look at a snap shot of the business growth. And finally – as a second measure of performance – we will look at the returns shareholders have received over the last few years. This method ...

143

Earnings

-$2.81
-$1.89
-$0.98
-$0.06
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.20 per share
Actual
Expected Today, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.